Jump to content

New predictor for lung cancer found

Recommended Posts

New predictor for lung cancer found

CLEVELAND, June 8 (UPI) -- U.S. researchers say they have found a promising, novel biomarker that may predict the survival of people with advanced lung cancer.

The researchers at the Ireland Cancer Center, operated by University Hospitals of Cleveland, say the biomarker can also predict a patient's response to treatment.

Dr. Afshin Dowlati, a hematologist-oncologist at the Ireland Cancer Center, found patients with a low level of the biomarker intercellular adhesion molecule-1, or ICAM, had a better chance of survival and an increased response to chemotherapy.

Dowlati analyzed data from a major national study and found the monoclonal antibody Bevacizumab (Avastin), in addition to standard therapy, was more effective than standard treatment alone for patients with advanced, non-squamous, non-small cell lung cancer.

"We believe this research confirms a significant new prognostic marker in lung cancer," said Dowlati. "Previously, it has been a challenge to identify those patients that will respond best to treatment and what their outcomes will be. This biomarker appears to serve as a much better predictor than gender, patients' overall health and sites of metastases."

The study was presented recently in Atlanta during the annual meeting of the American Society of Clinical Oncology.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.